NEW YORK, Sept. 9 /- Reportlinker.com announces that a new market research report is available in its catalogue: US Enzymes Market http://www.reportlinker.com/p091893/US-Enzymes-Market.html US demand to increase 5.1% annually through 2014 Demand for enzymes in the US is forecast to rise more than five percent annually to $2.7 billion in 2014. Solid industry growth in rece...

This post in KPLU 88.5's "Humanosphere" blog examines how former President Jimmy Carter gave the fight against neglected tropical diseases (NTDs) "a good first shove nearly 30 years ago," writing, "Neglected diseases like river blindness, Guinea worm, parasitic (lymphatic) elephantiasis and schistosomiasis have been in Carter's cross hairs since the ...

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

A new drug that showed promise in animal studies and an early clinical trial didn't improve disability among stroke patients, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

Soy isoflavone supplements did not decrease breast cancer cell proliferation in a randomized clinical trial, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

Increased exposure to sunlight may reduce the risk of both food allergies and eczema in children, according to a new scientific study published this week.

An experimental device for removing blood clots in stroke patients dramatically outperformed the standard mechanical treatment, according to research presented by UCLA Stroke Center director Dr. Jeffrey L. Saver at the American Stroke Association's 2012 international conference in New Orleans on Feb. 3.

Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.